You are here

Share:

Search Technologies

Showing 1-6 of 6 results found

Anti-CD133 Monoclonal Antibodies as Cancer Therapeutics

Researchers at NCI developed a rabbit monoclonal antibody that recognizes the marker for CD133 and is useful in pharmacodynamic testing to inform targeted anti-cancer chemotherapy development and clinical monitoring. CD133 is a cell surface glycoprotein used as a marker and expressed in stem cells such as hematopoietic stem cells, endothelial progenitor cells and neural stem cells. The NCI seeks collaborative co-development or licensing partners for this technology.

Diagnostic Assay for Determining Patient Response to Apoptosis-related Cancer Therapy

Researchers at the National Cancer Institute (NCI) developed a multiplex assay to determine the efficacy of apoptosis-related drugs targeting the Bcl2 family of proteins or aid in the selection of cancer patients likely to respond. The NCI seeks partners for co-development or licensees for commercialization of novel immunoassays for determining or predicting patient response to cancer therapy.

MADCO-Accelerated Multidimensional Diffusion MRI

The marginal distribution constrained optimization (MADCO) methodology is disclosed wherein a 2D (or higher-dimensional) spectrum is estimated from initial 1D marginal distribution data. These 1D marginal distributions are used as constraints in the reconstruction of the 2D spectra. MADCO accelerates and improves the reconstruction of multidimensional NMR relaxation/diffusion spectra, making it suitable for MRI applications on a voxel-by-voxel basis by vastly reducing the amount of data acquired and data necessary for creating MRI images.

Methods of analyzing virus-derived therapeutics

Researchers at the National Cancer Institute’s Biopharmaceutical Development Program recently developed massively parallel sequencing methods for virus-derived therapeutics such as viral vaccines and oncolytic immunotherapies, for which the NCI seeks licensees or co-development collaborations.

The Biospecimen Pre-analytical Variables (BPV) Program

The Biorepositories and Biospecimen Research Branch (BBRB) at the National Cancer Institute (NCI) has sponsored various initiatives for conducting biospecimen research. Through these initiatives, NCI seeks to advance biospecimen science and improve research reproducibility by investigating how different biospecimen collection, handling and processing procedures affect biospecimen molecular profiles. BBRB is seeking collaborators to extend these studies.